These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 19509144)

  • 1. Eribulin: rediscovering tubulin as an anticancer target.
    Jimeno A
    Clin Cancer Res; 2009 Jun; 15(12):3903-5. PubMed ID: 19509144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies.
    Goel S; Mita AC; Mita M; Rowinsky EK; Chu QS; Wong N; Desjardins C; Fang F; Jansen M; Shuster DE; Mani S; Takimoto CH
    Clin Cancer Res; 2009 Jun; 15(12):4207-12. PubMed ID: 19509177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial.
    Morgan RJ; Synold TW; Longmate JA; Quinn DI; Gandara D; Lenz HJ; Ruel C; Xi B; Lewis MD; Colevas AD; Doroshow J; Newman EM
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):897-907. PubMed ID: 26362045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eribulin mesylate (Halaven) for breast cancer.
    Med Lett Drugs Ther; 2011 Apr; 53(1362):30-1. PubMed ID: 21502935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eribulin mesylate for the treatment of breast cancer.
    Cigler T; Vahdat LT
    Expert Opin Pharmacother; 2010 Jun; 11(9):1587-93. PubMed ID: 20450446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eribulin mesylate for the treatment of late-stage breast cancer.
    Gourmelon C; Frenel JS; Campone M
    Expert Opin Pharmacother; 2011 Dec; 12(18):2883-90. PubMed ID: 22087618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perspectives on the mechanism of action and clinical application of eribulin for metastatic breast cancer.
    O'Shaughnessy J; Kaklamani V; Kalinsky K
    Future Oncol; 2019 May; 15(14):1641-1653. PubMed ID: 30892083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors.
    Tan AR; Rubin EH; Walton DC; Shuster DE; Wong YN; Fang F; Ashworth S; Rosen LS
    Clin Cancer Res; 2009 Jun; 15(12):4213-9. PubMed ID: 19509146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer.
    Cortes J; Montero AJ; Glück S
    Cancer Treat Rev; 2012 Apr; 38(2):143-51. PubMed ID: 21550727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eribulin mesylate in the management of metastatic breast cancer and other solid cancers: a drug review.
    Polastro L; Aftimos PG; Awada A
    Expert Rev Anticancer Ther; 2014 Jun; 14(6):649-65. PubMed ID: 24852360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical efficacy of eribulin mesylate for the treatment of metastatic soft tissue sarcoma.
    Emambux S; Italiano A
    Expert Opin Pharmacother; 2017 Jun; 18(8):819-824. PubMed ID: 28468516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eribulin mesylate in patients with refractory cancers: a Phase I study.
    Mukohara T; Nagai S; Mukai H; Namiki M; Minami H
    Invest New Drugs; 2012 Oct; 30(5):1926-33. PubMed ID: 21887501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eribulin: an effective therapeutic option in liposarcoma.
    Das M
    Lancet Oncol; 2017 Oct; 18(10):e569. PubMed ID: 28890295
    [No Abstract]   [Full Text] [Related]  

  • 14. Eribulin mesylate (E7389): review of efficacy and tolerability in breast, pancreatic, head and neck, and non-small cell lung cancer.
    Scarpace SL
    Clin Ther; 2012 Jul; 34(7):1467-73. PubMed ID: 22739019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in therapy: eribulin improves survival for metastatic breast cancer.
    Morris PG
    Anticancer Drugs; 2010 Nov; 21(10):885-9. PubMed ID: 20838209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of the halichondrin B analog eribulin mesylate in gemcitabine refractory advanced pancreatic cancer.
    Renouf DJ; Tang PA; Major P; Krzyzanowska MK; Dhesy-Thind B; Goffin JR; Hedley D; Wang L; Doyle L; Moore MJ
    Invest New Drugs; 2012 Jun; 30(3):1203-7. PubMed ID: 21526355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eribulin, a simplified ketone analog of the tubulin inhibitor halichondrin B, for the potential treatment of cancer.
    Newman S
    Curr Opin Investig Drugs; 2007 Dec; 8(12):1057-66. PubMed ID: 18058576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of eribulin mesylate in cancer patients with normal and impaired renal function.
    Tan AR; Sarantopoulos J; Lee L; Reyderman L; He Y; Olivo M; Goel S
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):1051-61. PubMed ID: 26433580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer.
    Ates O; Babacan T; Kertmen N; Sarici F; Cenoli A; Akin S; Karakas Y; Kilickap S; Ozisik Y; Sever AR; Aksoy S; Altundag K
    J BUON; 2016; 21(2):375-81. PubMed ID: 27273947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eribulin mesylate in breast cancer.
    Verdaguer H; Morilla I; Urruticoechea A
    Womens Health (Lond); 2013 Nov; 9(6):517-26. PubMed ID: 24161305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.